Advanced search
Publication Cover
Journal of Liposome Research Volume 32, 2022 - Issue 4
Submit an article Journal homepage
146
Views
1
CrossRef citations to date
0
Altmetric
Articles

Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy

Snehal Pardeshia Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
,
Amrendra Tiwaria Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, IndiaORCID Iconhttps://orcid.org/0000-0003-4477-3788
ORCID Icon,
Uday Titamea Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
,
Pankaj K Singha Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India;b Department of Pharmaceutics, NIPER Hyderabad, Hyderabad, IndiaORCID Iconhttps://orcid.org/0000-0001-8462-2170
ORCID Icon,
Pavan Kumar Yadava Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
&
Manish K. Chourasiaa Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, IndiaCorrespondence[email protected]
Pages 386-395 | Received 30 Sep 2021, Accepted 07 Feb 2022, Published online: 28 Feb 2022

References

  • Bruno, R, et al., 2003. Preliminary population pharmacokinetics (P P K) and exposure-safety (E-S) relationships of erlotinib HCI in patients with metastatic breast cancer (MBC). In: Proceedings of the American Society of Clinical Oncology (ASCO '03), vol. 22, p. 205, Chicago, Ill, USA, June 2003.
  • Buck, E., et al., 2006. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Molecular cancer therapeutics, 5 (8), 2051–2059.
  • Chin, T.M., et al., 2008. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment. Clinical cancer research, 14 (21), 6867–6876.
  • Daraee, H., et al., 2016. Application of liposomes in medicine and drug delivery. Artificial cells, nanomedicine, and biotechnology, 44 (1), 381–391.
  • Diep, C.H., et al., 2011. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical cancer research, 17 (9), 2744–2756.
  • Dimov, N., et al., 2017. Formation and purification of tailored liposomes for drug delivery using a module-based micro continuous-flow system. Scientific reports, 7, 120–145.
  • Dwivedi, C., and Verma, S., 2013. Review on preparation and characterization of liposomes with application. Journal of scientific and innovative research and reviews, 2, 2320–4818.
  • Gerlowski, L.E., and Jain, R.K., 1986. Microvascular permeability of normal and neoplastic tissues. Microvascular Research, 31 (3), 288–305.
  • Hao, J., Yang, X., et al., 2016. Paeoniflorin potentiates the inhibitory effects of erlotinib in pancreatic cancer cell lines by reducing ErbB3 phosphorylation. Scientific reports, 6, 1–9.
  • Hua, S., and Wu, S.Y., 2013. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in pharmacology, 4, 143–147.
  • Khare, V., et al., 2014. Targeted drug delivery systems for pancreatic cancer. Journal of biomedical nanotechnology, 10 (12), 3462–3482.
  • Latha, S.T., Thangadurai, S.A., et al., 2017. Development and validation of RP-HPLC method for the estimation of erlotinib in pharmaceutical formulation. Arabian Journal of Chemistry, 10, S1138–S1144.
  • Le, U.M., Hartman, A., and Pillai, G., 2017. Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFRoverexpressed pancreatic cancer cells. Journal ofdrug target, 1, 1–8.
  • Long, J., et al., 2011. Overcoming drug resistance in pancreatic cancer. Expert opinion on therapeutic targets, 15 (7), 817–828.
  • Maitra, A., and Hruban, R.H., 2008. Pancreatic cancer. Annual review of pathology, 3, 157–188.
  • Meure, L.A., Foster, N.R., and Dehghani, F., 2008. Conventional and dense gas techniques for the production of liposomes: a review. AAPS Pharmscitech, 9 (3), 798–809.
  • Pathak, S.K., et al., 2012. Effect of cholesterol concentration on size of liposome. IOSR journal of pharmacy and biological sciences, 1 (1), 50–53.
  • Provenzano, P.P., and Hingorani, S.R., 2013. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British journal of cancer, 108 (1), 1–8.
  • Ranson, M., et al., 2010. A Phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer chemotherapy and pharmacology, 66 (1), 53–58.
  • Saravanan, V.S., and Rao, B.M., 2013. Analytical method development and validation for the determination of erlotinib hydrochloride bulk and in pharmaceutical dosage form. Journal ofdrug delivery and therapy, 3, 50–54.
  • Segaert, S., and Cutsem, E.V., 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of oncology, 16 (9), 1425–1433. vol.
  • Singh, P.K., et al., 2016. Macrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasis. RSC Advances, 6 (75), 71705–71718.
  • Starling, N., Neoptolemos, J., and Cunningham, D., 2006. Role of erlotinib in the management of pancreatic cancer. Therapeutics and clinical risk management, 2 (4), 435–445.
  • Xu, H., et al., 2017. Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artificial Cells, Nanomedicine, and Biotechnology, 1–6. 10.1080/21691401.2017.1396222

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.